ArticleJournal of diabetes investigation2026
Mechanisms of hesperetin in alleviating diabetic nephropathy: Network pharmacology, molecular docking, and experimental validation.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy (DN) accounts for approximately 50% of chronic kidney disease cases. This study explored the potential regulatory mechanisms of hesperetin in DN.
methodsHigh glucose (HG)-treated HK-2 cells and streptozotocin (STZ)-induced diabetic mice were used as DN models. Impacts on cells were assessed by detecting viability, apoptosis, inflammatory cytokine release, and malondialdehyde (MDA), ferrous iron (Fe
resultsHesperetin increased cell viability and decreased apoptosis, the release of inflammatory cytokines, and the levels of MDA, Fe
conclusionsHesperetin alleviates DN progression by increasing cell viability and decreasing apoptosis, inflammatory cytokine release, and ferroptosis in HK-2 cells partially via modulating IGF1R expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.